These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 32166597)

  • 21. JAK-STAT signaling pathway inhibition: a role for treatment of various dermatologic diseases.
    Kahn J; Deverapalli SC; Rosmarin D
    Semin Cutan Med Surg; 2018 Sep; 37(3):198-208. PubMed ID: 30215638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Topical Janus kinase inhibitors: A review of applications in dermatology.
    Hosking AM; Juhasz M; Mesinkovska NA
    J Am Acad Dermatol; 2018 Sep; 79(3):535-544. PubMed ID: 29673776
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis.
    Zhang H; Watanabe R; Berry GJ; Tian L; Goronzy JJ; Weyand CM
    Circulation; 2018 May; 137(18):1934-1948. PubMed ID: 29254929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology.
    Cinats A; Heck E; Robertson L
    Skin Therapy Lett; 2018 May; 23(3):5-9. PubMed ID: 29772037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology.
    Kostovic K; Gulin SJ; Mokos ZB; Ceovic R
    Curr Med Chem; 2017 May; 24(11):1158-1167. PubMed ID: 28088907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases.
    Clark JD; Flanagan ME; Telliez JB
    J Med Chem; 2014 Jun; 57(12):5023-38. PubMed ID: 24417533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abrocitinib: First Approval.
    Deeks ED; Duggan S
    Drugs; 2021 Dec; 81(18):2149-2157. PubMed ID: 34807428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pharmacology of Janus kinase inhibitors].
    Solimani F; Hilke FJ; Ghoreschi K
    Hautarzt; 2019 Dec; 70(12):934-941. PubMed ID: 31740978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases.
    Alves de Medeiros AK; Speeckaert R; Desmet E; Van Gele M; De Schepper S; Lambert J
    PLoS One; 2016; 11(10):e0164080. PubMed ID: 27711196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of Delgocitinib Ointment 0.5% on the Normal Mouse Skin and Epidermal Tight Junction Proteins in Comparison With Topical Corticosteroids.
    Anagawa-Nakamura A; Ryoke K; Yasui Y; Shoda T; Sugai S
    Toxicol Pathol; 2020 Dec; 48(8):1008-1016. PubMed ID: 33334258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.
    Flanagan ME; Blumenkopf TA; Brissette WH; Brown MF; Casavant JM; Shang-Poa C; Doty JL; Elliott EA; Fisher MB; Hines M; Kent C; Kudlacz EM; Lillie BM; Magnuson KS; McCurdy SP; Munchhof MJ; Perry BD; Sawyer PS; Strelevitz TJ; Subramanyam C; Sun J; Whipple DA; Changelian PS
    J Med Chem; 2010 Dec; 53(24):8468-84. PubMed ID: 21105711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
    Roskoski R
    Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging Topical and Systemic JAK Inhibitors in Dermatology.
    Solimani F; Meier K; Ghoreschi K
    Front Immunol; 2019; 10():2847. PubMed ID: 31849996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. JAK inhibitor selectivity: new opportunities, better drugs?
    Virtanen A; Spinelli FR; Telliez JB; O'Shea JJ; Silvennoinen O; Gadina M
    Nat Rev Rheumatol; 2024 Oct; 20(10):649-665. PubMed ID: 39251770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy of Janus kinase inhibitors in patients with atopic dermatitis: A systematic review and network meta-analysis.
    Zhang L; Wang L; Jiang X
    Dermatol Ther; 2021 Sep; 34(5):e15098. PubMed ID: 34392600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. JAK inhibitors: Ten years after.
    Spinelli FR; Meylan F; O'Shea JJ; Gadina M
    Eur J Immunol; 2021 Jul; 51(7):1615-1627. PubMed ID: 33930196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. JAK1/JAK2 degraders based on PROTAC for topical treatment of atopic dermatitis.
    Wu J; Li L; Zhu Q; Zhang T; Miao F; Cui Z; Dong G; Tai Z; Chen Z
    Biomed Pharmacother; 2024 Feb; 171():116167. PubMed ID: 38262152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis.
    Fragoulis GE; McInnes IB; Siebert S
    Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i43-i54. PubMed ID: 30806709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Development of new topical substances for the treatment of atopic dermatitis].
    Freimooser S; Traidl S; Werfel T
    Dermatologie (Heidelb); 2022 Jul; 73(7):514-519. PubMed ID: 35608634
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhaled Janus Kinase (JAK) inhibitors for the treatment of asthma.
    Zak M; Dengler HS; Rajapaksa NS
    Bioorg Med Chem Lett; 2019 Oct; 29(20):126658. PubMed ID: 31522830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.